Insulin Biosimilars - Global Market Outlook (2017-2023)

Friday, January 12, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Jan. 11, 2018 /PRNewswire/ -- Stratistics MRC, are pleased to announce the latest publication of Global Insulin Biosimilars

market. Growing pervasiveness of type 1 diabetes and ongoing approvals by the government authorities are nurturing the market growth. Download the full report: https://www.reportbuyer.com/product/4300260 Some of the factors such as growing population
exposures, technological developments and favorable medical repayment scenario in developed countries are poised to favour the market growth. However, patent protection rights of insulin and strong vengeance from the key manufacturers are some of the restraints limiting the market. Expansion of clinically verified insulin biosimilar will cover the road for new entrants. The approaching patent expiration of insulin drugs will unlock new opportunities for the development of biosimilars and manufacturing companies. As cost is high due to strict observance requirements, prices of biosimilar drugs are anticipated to decrease as compared to branded drugs. North America led the insulin biosimilars market due to rising demand for insulin in the region. Europe is anticipated to account for second largest share and Asia Pacific is expected to grow at a fastest rate during the forecast period. APAC players are competing on the basis of price and have pool of patients affected by diabetes, thus fueling the market growth. Some of the key players in this market are Wockhardt Limited, Ypsomed AG, Pfizer Inc., Mylan N.V., Boehringer Ingelheim GmbH, NOVO Nordisk A/S, Sanofi S.A., Merck & Co., Biocon Limited and Eli Lilly & Co. Biosimilars Types Covered: • Rapid-Acting Biosimilars • Long-Acting Biosimilars • Premixed Biosimilars Disease Indications Covered: • Type I Diabetes • Type II Diabetes Regions Covered:North America o US o Canada o MexicoEurope o Germany o U.K. o Italy o France o Spain o Rest of EuropeAsia Pacific o Japan o China o India o Australia o New Zealand o South Korea o Rest of Asia PacificSouth America o Argentina o Brazil o Chile o Rest of South AmericaMiddle East & Africa o Saudi Arabia o UAE o Qatar o South Africa o Rest of Middle East & Africa What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancementsDownload the full report: https://www.reportbuyer.com/product/4300260 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com  Tel: +1 (646) 453 6293 Website: www.reportbuyer.com  

Cision View original content:http://www.prnewswire.com/news-releases/insulin-biosimilars---global-market-outlook-2017-2023-300581624.html

SOURCE ReportBuyer

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store